THE DEFINITIVE GUIDE TO KEYTRUDA COST

Assessment Pembrolizumab (Keytruda): CADTH Reimbursement Suggestion: Indicator: In combination with chemotherapy, for your treatment of adult individuals with regionally recurrent unresectable or metastatic triple-destructive breast cancer who may have not been given prior chemotherapy for metastatic illness and whose tumours Specific programmed ce